MyFinsight
Home
Blog
About
Proceeds from maturity
and redemption of...
$37,319K
(224.51%↑ Y/Y)
Net cash provided by
(used in) investing...
$17,754K
(116.74%↑ Y/Y)
Canceled cashflow
$19,565K
Net increase
(decrease) in cash and cash...
$2,339K
(101.78%↑ Y/Y)
Canceled cashflow
$15,415K
Purchase of marketable
debt securities
$19,233K
(-83.63%↓ Y/Y)
Purchase of property and
equipment
$332K
(403.03%↑ Y/Y)
Accrued expenses and
other current...
$3,743K
(274.50%↑ Y/Y)
Stock-based compensation
$1,384K
(-20.28%↓ Y/Y)
Prepaid expenses and
other current assets
-$965K
(-195.36%↓ Y/Y)
Operating lease
right-of-use asset
$289K
(-45.47%↓ Y/Y)
Accounts payable
$243K
(-83.63%↓ Y/Y)
Depreciation
$72K
(-60.22%↓ Y/Y)
Other assets
-$60K
(70.59%↑ Y/Y)
Net cash provided by
(used in) operating...
-$15,389K
(42.93%↑ Y/Y)
Net cash provided by
(used in) financing...
-$26K
(-101.50%↓ Y/Y)
Canceled cashflow
$6,756K
Net income (loss)
-$21,668K
(19.37%↑ Y/Y)
Taxes paid related to
net share...
$26K
(-85.95%↓ Y/Y)
Operating lease
liabilities
-$308K
(42.43%↑ Y/Y)
Amortization of premium
(accretion of discount) on...
-$169K
(68.23%↑ Y/Y)
Back
Back
Cash Flow
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)
source: myfinsight.com